Real-World data shows promise for CNCT-19 in tough leukemia
NCT ID NCT07269587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well a treatment called CNCT-19 works for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia (ALL). Researchers will review medical records from 275 patients across multiple hospitals in China to see how many achieve remission and how long it lasts. The goal is to understand the real-world benefits and risks of this therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL (ACUTE B-LYMPHOBLASTIC LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas